STOCK TITAN

[25-NSE] ESSA Pharma Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
25-NSE

Nasdaq has submitted a Form 25 to remove the listing of ESSA Pharma Inc. The filing names the issuer as ESSA Pharma Inc. (symbol EPIX) with principal offices in Vancouver, British Columbia. The form cites compliance with the Exchange's procedures under the federal rules that govern delisting and voluntary withdrawal but does not state the reason, effective date, or indicate which specific rule provision was checked. No financial results, transactions, or timelines are included.

Nasdaq ha presentato un Modulo 25 per rimuovere l'elenco di ESSA Pharma Inc. L'atto nomina l'emittente come ESSA Pharma Inc. (simbolo EPIX) con uffici principali a Vancouver, Columbia Britannica. Il modulo cita la conformità alle procedure della Borsa secondo le norme federali che regolano il delisting e il ritiro volontario, ma non indica il motivo, la data di efficacia, né specifica quale disposizione di regola sia stata verificata. Nessun risultato finanziario, transazioni o cronologia sono inclusi.

Nasdaq ha presentado un Formulario 25 para retirar la cotización de ESSA Pharma Inc. La solicitud nombra al emisor como ESSA Pharma Inc. (símbolo EPIX) con oficinas principales en Vancouver, Columbia Británica. El formulario cita el cumplimiento de los procedimientos de la Bolsa bajo las reglas federales que rigen el delistado y el retiro voluntario, pero no indica la razón, la fecha efectiva, ni señala qué disposición regulatoria específica se marcó. No se incluyen resultados financieros, transacciones ni cronogramas.

나스닥이 ESSA Pharma Inc.의 상장 제거를 위한 양식 25를 제출했습니다. 제출 서류는 발행인을 ESSA Pharma Inc. (심볼 EPIX)으로 명시하며 본사는 캐나다 브리티시컬럼비아주 밴쿠버에 있다고 기재합니다. 양식은 상장폐지 및 자진철회의 적용 규정에 따라 연방 규칙에 따른 절차 준수를 언급하지만 사유, 효력발생일, 또는 어떤 특정 규정 조항이 확인되었는지는 명시하지 않습니다. 재무 결과, 거래 또는 일정은 포함되어 있지 않습니다.

Nasdaq a soumis un Formulaire 25 pour retirer la cotation de ESSA Pharma Inc. Le dépôt désigne l'émetteur comme ESSA Pharma Inc. (symbole EPIX) dont le siège principal est à Vancouver, Colombie-Britannique. Le formulaire évoque le respect des procédures de l'échange en vertu des règles fédérales régissant le retrait et le retrait volontaire, mais il n'indique ni la raison, ni la date d'effet, ni précise quelle disposition réglementaire spécifique a été cochée. Aucune information financière, transaction ou échéancier n'est inclus.

Nasdaq hat Formular 25 eingereicht, um die Börsennotierung von ESSA Pharma Inc. zu entfernen. Die Einreichung benennt den Emittenten als ESSA Pharma Inc. (Symbol EPIX) mit Hauptsitz in Vancouver, British Columbia. Das Formular verweist auf die Einhaltung der Verfahren der Börse gemäß den bundesstaatlichen Bestimmungen, die das Delisting und den freiwilligen Rückzug regeln, gibt jedoch keinen Grund an, kein Wirksamkeitsdatum, noch welche spezifische Rechtsvorschrift überprüft wurde. Keine finanziellen Ergebnisse, Transaktionen oder Zeitpläne sind enthalten.

قدمت Nasdaq نموذج 25 لإزالة إدراج ESSA Pharma Inc. يذكر الملف المصدر كـ ESSA Pharma Inc. (الرمز EPIX) ويقع المكتب الرئيسي في فانكوفر، كولومبيا البريطانية. يشير النموذج إلى الامتثال لإجراءات البورصة بموجب القواعد الاتحادية التي تحكم إزالة الإدراج والسحب الطوعي، ولكنه لا يذكر السبب أو تاريخ السريان، ولا يشير إلى أي حكم من القاعدة تم التحقق منه بالتحديد. لا تتضمن النتائج المالية أو المعاملات أو الجداول الزمنية.

纳斯达克已提交表格25以撤销ESSA Pharma Inc.的上市。该表格将发行人列为 ESSA Pharma Inc.(代码 EPIX),总部位于不列颠哥伦比亚省温哥华市。表格引用遵守交易所按联邦法规监管的退市及自愿退市程序,但未说明原因、 生效日期,或指出检查了哪个特定的规则条款。未包含财务结果、交易或时间表。

Positive
  • None.
Negative
  • Listing removal notice filed without an effective date or reason disclosed

Insights

Form 25 notifies investors that the company's Nasdaq listing will be removed, without stating a date or reason.

The filing confirms that Nasdaq submitted a Form 25 for ESSA Pharma Inc. (EPIX) and asserts compliance with the Exchange's internal rules and applicable federal regulations for delisting or voluntary withdrawal. The document lists the issuer's principal address and contact number but includes no operational or financial details explaining the action.

The main dependencies are procedural: whether the removal is voluntary or initiated by Nasdaq and the timing of the removal. Absent a stated effective date or cause, the near-term item to watch is any follow-up filing (an attached Notice or a company statement) that discloses the effective date or reason within typical regulatory timelines.

Nasdaq ha presentato un Modulo 25 per rimuovere l'elenco di ESSA Pharma Inc. L'atto nomina l'emittente come ESSA Pharma Inc. (simbolo EPIX) con uffici principali a Vancouver, Columbia Britannica. Il modulo cita la conformità alle procedure della Borsa secondo le norme federali che regolano il delisting e il ritiro volontario, ma non indica il motivo, la data di efficacia, né specifica quale disposizione di regola sia stata verificata. Nessun risultato finanziario, transazioni o cronologia sono inclusi.

Nasdaq ha presentado un Formulario 25 para retirar la cotización de ESSA Pharma Inc. La solicitud nombra al emisor como ESSA Pharma Inc. (símbolo EPIX) con oficinas principales en Vancouver, Columbia Británica. El formulario cita el cumplimiento de los procedimientos de la Bolsa bajo las reglas federales que rigen el delistado y el retiro voluntario, pero no indica la razón, la fecha efectiva, ni señala qué disposición regulatoria específica se marcó. No se incluyen resultados financieros, transacciones ni cronogramas.

나스닥이 ESSA Pharma Inc.의 상장 제거를 위한 양식 25를 제출했습니다. 제출 서류는 발행인을 ESSA Pharma Inc. (심볼 EPIX)으로 명시하며 본사는 캐나다 브리티시컬럼비아주 밴쿠버에 있다고 기재합니다. 양식은 상장폐지 및 자진철회의 적용 규정에 따라 연방 규칙에 따른 절차 준수를 언급하지만 사유, 효력발생일, 또는 어떤 특정 규정 조항이 확인되었는지는 명시하지 않습니다. 재무 결과, 거래 또는 일정은 포함되어 있지 않습니다.

Nasdaq a soumis un Formulaire 25 pour retirer la cotation de ESSA Pharma Inc. Le dépôt désigne l'émetteur comme ESSA Pharma Inc. (symbole EPIX) dont le siège principal est à Vancouver, Colombie-Britannique. Le formulaire évoque le respect des procédures de l'échange en vertu des règles fédérales régissant le retrait et le retrait volontaire, mais il n'indique ni la raison, ni la date d'effet, ni précise quelle disposition réglementaire spécifique a été cochée. Aucune information financière, transaction ou échéancier n'est inclus.

Nasdaq hat Formular 25 eingereicht, um die Börsennotierung von ESSA Pharma Inc. zu entfernen. Die Einreichung benennt den Emittenten als ESSA Pharma Inc. (Symbol EPIX) mit Hauptsitz in Vancouver, British Columbia. Das Formular verweist auf die Einhaltung der Verfahren der Börse gemäß den bundesstaatlichen Bestimmungen, die das Delisting und den freiwilligen Rückzug regeln, gibt jedoch keinen Grund an, kein Wirksamkeitsdatum, noch welche spezifische Rechtsvorschrift überprüft wurde. Keine finanziellen Ergebnisse, Transaktionen oder Zeitpläne sind enthalten.

UNITED STATES
OMB APPROVAL
OMB Number: 3235-0080
Expires: March 31, 2018
Estimated average burden
hours per response: 1.7
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 25
NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
Commission File Number 001-37410
Issuer: ESSA Pharma Inc.
Exchange: Nasdaq Stock Market LLC
(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
Address: 999 West Broadway, Suite 720
Vancouver BRITISH COLUMBIA, CANADA V5Z 1K5
Telephone number: (778)-331-0962
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock
(Description of class of securities)
Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
17 CFR 240.12d2-2(a)(1)
17 CFR 240.12d2-2(a)(2)
17 CFR 240.12d2-2(a)(3)
17 CFR 240.12d2-2(a)(4)
Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
2025-10-09 By Tara Petta AVP
Date Name Title
1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 filed for ESSA Pharma (EPIX) mean?

The Form 25 indicates Nasdaq has submitted a notification to remove or withdraw the company's class of securities from Nasdaq listing; the filing does not state an effective date or the reason.

Does the filing say whether the delisting was voluntary or involuntary for EPIX?

No. The filing states compliance with Exchange rules for delisting and withdrawal but does not specify whether the action is voluntary or initiated by Nasdaq.

What company contact information is included in the Form 25 for ESSA Pharma?

The filing lists the issuer's address as 999 West Broadway, Suite 720, Vancouver, British Columbia and telephone number (778)-331-0962.

Are there any financial results or transactions disclosed in this Form 25?

No. The filing contains no earnings data, financial tables explaining the action, or transaction details.

What should investors watch for after this Form 25 filing for EPIX?

Investors should look for follow-up disclosures that provide an effective date, the specific rule provision applied, or a company statement explaining the reason for removal.
Essa Pharma

NASDAQ:EPIX

EPIX Rankings

EPIX Latest News

EPIX Latest SEC Filings

EPIX Stock Data

9.70M
44.65M
5.64%
74.16%
7.74%
Biotechnology
Pharmaceutical Preparations
Link
Canada
VANCOUVER